Etavopivat Filed With FDA and EMA: Novo Nordisk Takes Sickle Cell Pill to Regulators
Novo Nordisk has filed once-daily etavopivat for sickle cell disease with the FDA and EMA after HIBISCUS cut crises by 27%. How it compares with mitapivat.
Novo Nordisk has filed once-daily etavopivat for sickle cell disease with the FDA and EMA after HIBISCUS cut crises by 27%. How it compares with mitapivat.